Advertisement

Optical coherence tomography angiography features of chorioretinal folds: a case series

Abstract

Purpose

To report 3 cases of ocular chorioretinal folds from different etiologies and their aspect with the new imaging technology of optical coherence tomography (OCT) angiography (OCT-A).

Methods

Baseline data, investigational process on etiology, and follow-up data of patients referred for chorioretinal folds to the Medical Retina & Imaging Unit of San Raffaele Hospital in the period January-March 2016 were collected. Multimodal imaging evaluation, comprehensive of infrared, fundus autofluorescence, multicolor, spectral-domain OCT, and OCT-A, was performed on all patients.

Results

Four eyes of 3 men, 65, 46, and 50 years of age, showed chorioretinal folds secondary to central serous chorioretinopathy, postoperative hypotony (after deep sclerectomy), and anisometropia with unilateral hyperopia, respectively. In all cases, OCT-A imaging showed a signal reduction in the choriocapillaris layer in correspondence of the folds. Due to this signal reduction, the en face reconstruction of choriocapillaris layer showed, in all cases, a peculiar tigroid aspect. The aspect of the folds at OCT-A remained unchanged during the 3-month follow-up in all patients.

Conclusions

Optical coherence tomography angiography shows a typical linear signal reduction in the choriocapillaris layer in correspondence of the fold with a tigroid pattern. We hypothesize this aspect could be explained by blood flow alteration at the choriocapillaris level in correspondence of the fold.

Eur J Ophthalmol 2017; 27(2): e35 - e38

Article Type: CASE REPORT

DOI:10.5301/ejo.5000872

Authors

Claudia Del Turco, Alessandro Rabiolo, Adriano Carnevali, Carlo La Spina, Paolo Bettin, Giuseppe Querques, Francesco Bandello

Article History

Disclosures

Financial support: F. Bandello: advisory board member: Allergan, Inc.; Novartis Pharmaceuticals Corporation; Farmila-Thea; Bayer Schering Pharma; Pfizer, Inc.; Alcon, Inc.; Bausch and Lomb; Genentech, Inc.; Alimera Sciences, Inc.; Thrombogenics, Inc.
Conflict of interest: None of the authors has conflict of interest with this submission.

This article is available as full text PDF.

  • If you are a Subscriber, please log in now.

  • Article price: Eur 36,00
  • You will be granted access to the article for 72 hours and you will be able to download any format (PDF or ePUB). The article will be available in your login area under "My PayPerView". You will need to register a new account (unless you already own an account with this journal), and you will be guided through our online shop. Online purchases are paid by Credit Card through PayPal.
  • If you are not a Subscriber you may:
  • Subscribe to this journal
  • Unlimited access to all our archives, 24 hour a day, every day of the week.

Authors

Affiliations

  •  Department of Ophthalmology, IRCCS Ospedale San Raffaele, University Vita-Salute, Milan - Italy
  •  Department of Ophthalmology, University “Magna Graecia”, Catanzaro - Italy

Article usage statistics

The blue line displays unique views in the time frame indicated.
The yellow line displays unique downloads.
Views and downloads are counted only once per session.

No supplementary material is available for this article.